NCT01432938View on ClinicalTrials.gov

A Study of the Effect of Dulaglutide on the Action of Warfarin in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Diabetes Mellitus, Type 2
Interventions
BIOLOGICAL

dulaglutide

Administered subcutaneously

DRUG

Warfarin

Administered orally

Trial Locations (1)

75247

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT01432938 - A Study of the Effect of Dulaglutide on the Action of Warfarin in Healthy Participants | Biotech Hunter | Biotech Hunter